

Michael H Baumann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1320826/publications.pdf>

Version: 2024-02-01

215
papers

11,957
citations

32410

55
h-index

38517

99
g-index

217
all docs

217
docs citations

217
times ranked

8562
citing authors

#	ARTICLE	IF	CITATIONS
1	(2-Aminopropyl)benzo[¹²]thiophenes (APBTs) are novel monoamine transporter ligands that lack stimulant effects but display psychedelic-like activity in mice. <i>Neuropsychopharmacology</i> , 2022, 47, 914-923.	2.8	8
2	Structure-activity relationships for 5F-MDMB-PICA and its 5F-pentylindole analogs to induce cannabinoid-like effects in mice. <i>Neuropsychopharmacology</i> , 2022, 47, 924-932.	2.8	9
3	Characterization of recent non-fentanyl synthetic opioids via three different in vitro $\hat{\mu}$ -opioid receptor activation assays. <i>Archives of Toxicology</i> , 2022, 96, 877-897.	1.9	10
4	Automated Computer Software Assessment of 5-Hydroxytryptamine 2A Receptor-Mediated Head Twitch Responses from Video Recordings of Mice. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 321-330.	2.5	9
5	First identification, chemical analysis and pharmacological characterization of N-piperidinyl etonitazene (etonitazepipne), a recent addition to the 2-benzylbenzimidazole opioid subclass. <i>Archives of Toxicology</i> , 2022, 96, 1865-1880.	1.9	12
6	Pharmacological evaluation and forensic case series of N-pyrrolidino etonitazene (etonitazepyne), a newly emerging 2-benzylbenzimidazole $\hat{\epsilon}$ -nitazene TM synthetic opioid. <i>Archives of Toxicology</i> , 2022, 96, 1845-1863.	1.9	22
7	Synthesis, Structural Characterization, and Pharmacological Activity of Novel Quaternary Salts of 4-Substituted Tryptamines. <i>ACS Omega</i> , 2022, 7, 24888-24894.	1.6	10
8	Amphetamine-like Neurochemical and Cardiovascular Effects of $\hat{\pm}$ -Ethylphenethylamine Analogs Found in Dietary Supplements. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 376, 118-126.	1.3	4
9	Selectivity and sensitivity of urine fentanyl test strips to detect fentanyl analogues in illicit drugs. <i>International Journal of Drug Policy</i> , 2021, 90, 103065.	1.6	43
10	Analysis for Alpha-Pyrrolidinovalerophenone and Its 2-Oxo-PVP Metabolite in Plasma by Liquid Chromatography $\hat{\epsilon}$ Tandem Mass Spectrometry. <i>Journal of Analytical Toxicology</i> , 2021, 45, 21-27.	1.7	0
11	Optogenetic brain $\hat{\epsilon}$ stimulation reward: A new procedure to re $\hat{\epsilon}$ evaluate the rewarding $\hat{\epsilon}$ versus $\hat{\epsilon}$ aversive effects of cannabinoids in dopamine transporter $\hat{\epsilon}$ Cre mice. <i>Addiction Biology</i> , 2021, 26, e13005.	1.4	19
12	Eutylone and Its Structural Isomers Interact with Monoamine Transporters and Induce Locomotor Stimulation. <i>ACS Chemical Neuroscience</i> , 2021, 12, 1170-1177.	1.7	14
13	Brain Concentrations of Methylone and Its Metabolites after Systemic Methylone Administration: Relationship to Pharmacodynamic Effects. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 377, 398-406.	1.3	8
14	Pharmacokinetics and pharmacodynamics of the synthetic cannabinoid, 5F-MDMB-PICA, in male rats. <i>Neuropharmacology</i> , 2021, 199, 108800.	2.0	7
15	Pharmacokinetics and pharmacodynamics of cyclopropylfentanyl in male rats. <i>Psychopharmacology</i> , 2021, 238, 3629-3641.	1.5	6
16	Comparative Neuropharmacology and Pharmacokinetics of Methamphetamine and Its Thiophene Analog Methiopropamine in Rodents. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12002.	1.8	6
17	Stereoselective neurochemical, behavioral, and cardiovascular effects of $\hat{\pm}$ -pyrrolidinovalerophenone enantiomers in male rats. <i>Addiction Biology</i> , 2020, 25, e12842.	1.4	11
18	U-47700 and Its Analogs: Non-Fentanyl Synthetic Opioids Impacting the Recreational Drug Market. <i>Brain Sciences</i> , 2020, 10, 895.	1.1	29

#	ARTICLE	IF	CITATIONS
19	The psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats. <i>Psychopharmacology</i> , 2020, 237, 3703-3714.	1.5	12
20	Syntheses and analytical characterizations of novel (2-aminopropyl)benzo[b]thiophene (APBT) based stimulants. <i>Drug Testing and Analysis</i> , 2020, 12, 1109-1125.	1.6	2
21	Pharmacodynamics and pharmacokinetics of the novel synthetic opioid, U-47700, in male rats. <i>Neuropharmacology</i> , 2020, 177, 108195.	2.0	15
22	Cell-Based Radiotracer Binding and Uptake Inhibition Assays: A Comparison of In Vitro Methods to Assess the Potency of Drugs That Target Monoamine Transporters. <i>Frontiers in Pharmacology</i> , 2020, 11, 673.	1.6	13
23	Transcranial photoacoustic imaging of NMDA-evoked focal circuit dynamics in the rat hippocampus. <i>Journal of Neural Engineering</i> , 2020, 17, 025001.	1.8	21
24	Confronting the opioid crisis with basic research in neuropharmacology. <i>Neuropharmacology</i> , 2020, 166, 107972.	2.0	5
25	Positive Allosteric Modulation of the 5-HT _{1A} Receptor by Indole-Based Synthetic Cannabinoids Abused by Humans. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1400-1405.	1.7	19
26	Metabolites of the ring-substituted stimulants MDMA, methylone and MDPV differentially affect human monoaminergic systems. <i>Journal of Psychopharmacology</i> , 2019, 33, 831-841.	2.0	23
27	2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α -adrenergic receptors. <i>Psychopharmacology</i> , 2019, 236, 989-999.	1.5	3
28	The Supplement Adulterant <i>l</i> -Methylphenethylamine Increases Blood Pressure by Acting at Peripheral Norepinephrine Transporters. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 369, 328-336.	1.3	6
29	Evidence for nonlinear accumulation of the ultrapotent fentanyl analog, carfentanil, after systemic administration to male rats. <i>Neuropharmacology</i> , 2019, 158, 107596.	2.0	17
30	Newly Developed Dopamine D ₃ Receptor Antagonists, <i>l</i> -VK4-40 and <i>l</i> -VK4-116, Do Not Potentiate Cardiovascular Effects of Cocaine or Oxycodone in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 371, 602-614.	1.3	24
31	Analytical quantification, intoxication case series, and pharmacological mechanism of action for N-ethylnorpentylone (N-ethylpentylone or ephylone). <i>Drug Testing and Analysis</i> , 2019, 11, 461-471.	1.6	39
32	The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes. <i>Psychopharmacology</i> , 2019, 236, 915-924.	1.5	12
33	The synthetic cathinones, butylone and pentylone, are stimulants that act as dopamine transporter blockers but 5-HT transporter substrates. <i>Psychopharmacology</i> , 2019, 236, 953-962.	1.5	20
34	Systematic Structure-Activity Studies on Selected 2-, 3-, and 4-Monosubstituted Synthetic Methcathinone Analogs as Monoamine Transporter Releasing Agents. <i>ACS Chemical Neuroscience</i> , 2019, 10, 740-745.	1.7	11
35	Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats. <i>Neuropharmacology</i> , 2018, 142, 240-250.	2.0	42
36	Synthesis, analytical characterization, and monoamine transporter activity of the new psychoactive substance 4-methylphenmetrazine (4-MPM), with differentiation from its <i>ortho</i> - and <i>meta</i> - positional isomers. <i>Drug Testing and Analysis</i> , 2018, 10, 1404-1416.	1.6	8

#	ARTICLE	IF	CITATIONS
37	Effects of <i>N</i> -Alkyl-4-Methylamphetamine Optical Isomers on Plasma Membrane Monoamine Transporters and Abuse-Related Behavior. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1829-1839.	1.7	10
38	Fluorinated phenmetrazine "legal highs" act as substrates for high-affinity monoamine transporters of the SLC6 family. <i>Neuropharmacology</i> , 2018, 134, 149-157.	2.0	22
39	Novel Synthetic Opioids and Overdose Deaths: Tip of the Iceberg?. <i>Neuropsychopharmacology</i> , 2018, 43, 216-217.	2.8	14
40	Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace. <i>Neuropharmacology</i> , 2018, 134, 101-107.	2.0	78
41	Pharmacological Research as a Key Component in Mitigating the Opioid Overdose Crisis. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 995-998.	4.0	47
42	Neuropharmacology of Synthetic Cathinones. <i>Handbook of Experimental Pharmacology</i> , 2018, 252, 113-142.	0.9	61
43	Pharmacodynamic Effects, Pharmacokinetics, and Metabolism of the Synthetic Cannabinoid AM-2201 in Male Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 367, 543-550.	1.3	17
44	The abuse-related effects of pyrrolidine-containing cathinones are related to their potency and selectivity to inhibit the dopamine transporter. <i>Neuropsychopharmacology</i> , 2018, 43, 2399-2407.	2.8	64
45	Repeated Exposure to the "Spice" Cannabinoid JWH-018 Induces Tolerance and Enhances Responsiveness to 5-HT _{1A} Receptor Stimulation in Male Rats. <i>Frontiers in Psychiatry</i> , 2018, 9, 55.	1.3	23
46	Enduring Loss of Serotonergic Control of Orbitofrontal Cortex Function Following Contingent and Noncontingent Cocaine Exposure. <i>Cerebral Cortex</i> , 2017, 27, 5463-5476.	1.6	6
47	Disruption of hippocampal synaptic transmission and long-term potentiation by psychoactive synthetic cannabinoid "Spice" compounds: comparison with I ⁹ -tetrahydrocannabinol. <i>Addiction Biology</i> , 2017, 22, 390-399.	1.4	36
48	Analytical characterization and pharmacological evaluation of the new psychoactive substance 4-fluoromethylphenidate (4F-MPH) and differentiation between the (±)-threo and (±)-erythro diastereomers. <i>Drug Testing and Analysis</i> , 2017, 9, 347-357.	1.6	14
49	Deconstructed Analogues of Bupropion Reveal Structural Requirements for Transporter Inhibition versus Substrate-Induced Neurotransmitter Release. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1397-1403.	1.7	22
50	Atypical dopamine efflux caused by 3,4-methylenedioxypyrovalerone (MDPV) via the human dopamine transporter. <i>Journal of Chemical Neuroanatomy</i> , 2017, 83-84, 69-74.	1.0	17
51	N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability. <i>Neuropsychopharmacology</i> , 2017, 42, 1950-1961.	2.8	26
52	Synthetic cannabinoids found in "spice" products alter body temperature and cardiovascular parameters in conscious male rats. <i>Drug and Alcohol Dependence</i> , 2017, 179, 387-394.	1.6	34
53	Conformational state interactions provide clues to the pharmacochaperone potential of serotonin transporter partial substrates. <i>Journal of Biological Chemistry</i> , 2017, 292, 16773-16786.	1.6	34
54	Trace amine-associated receptor 1 regulation of methamphetamine-induced neurotoxicity. <i>NeuroToxicology</i> , 2017, 63, 57-69.	1.4	33

#	ARTICLE	IF	CITATIONS
55	Misuse of Novel Synthetic Opioids: A Deadly New Trend. <i>Journal of Addiction Medicine</i> , 2017, 11, 256-265.	1.4	225
56	Impact of Novel Psychoactive Substances on Clinical and Forensic Toxicology and Global Public Health. <i>Clinical Chemistry</i> , 2017, 63, 1564-1569.	1.5	31
57	Synthesis, characterization and monoamine transporter activity of the new psychoactive substance mexedrone and its <i>N</i> -methoxy positional isomer, <i>N</i> -methoxymephedrone. <i>Drug Testing and Analysis</i> , 2017, 9, 358-368.	1.6	23
58	Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats. <i>Neuropsychopharmacology</i> , 2017, 42, 649-660.	2.8	27
59	Fentanyl-related designer drugs W-18 and W-15 lack appreciable opioid activity in vitro and in vivo. <i>JCI Insight</i> , 2017, 2, .	2.3	14
60	Cadherin 13: Human cis-Regulation and Selectively Altered Addiction Phenotypes and Cerebral Cortical Dopamine in Knockout Mice. <i>Molecular Medicine</i> , 2016, 22, 537-547.	1.9	26
61	Pharmacological mechanisms underlying the cardiovascular effects of the <i>α</i> -bath salt-constituent 3,4-methylenedioxypyrovalerone (MDPV). <i>British Journal of Pharmacology</i> , 2016, 173, 3492-3501.	2.7	69
62	Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs. <i>Current Topics in Behavioral Neurosciences</i> , 2016, 32, 93-117.	0.8	113
63	Quantification of [1-(5-fluoropentyl)-1H-indol-3-yl](naphthalene-1-yl)methanone (AM-2201) and 13 metabolites in human and rat plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2016, 1451, 97-106.	1.8	6
64	The biogenic amine transporter activity of vinyllogous amphetamine analogs. <i>MedChemComm</i> , 2016, 7, 1657-1663.	3.5	4
65	Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects. <i>Addiction Biology</i> , 2016, 21, 339-347.	1.4	83
66	Abuse-related neurochemical and behavioral effects of cathinone and 4-methylcathinone stereoisomers in rats. <i>European Neuropsychopharmacology</i> , 2016, 26, 288-297.	0.3	20
67	Binding Mode Selection Determines the Action of Ecstasy Homologs at Monoamine Transporters. <i>Molecular Pharmacology</i> , 2016, 89, 165-175.	1.0	53
68	Reinforcing and neurochemical effects of the <i>α</i> -bath salts-constituents 3,4-methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxy-N-methylcathinone (methylone) in male rats. <i>Psychopharmacology</i> , 2016, 233, 1981-1990.	1.5	87
69	The new psychoactive substances 5-(2-aminopropyl)indole (5-IT) and 6-(2-aminopropyl)indole (6-IT) interact with monoamine transporters in brain tissue. <i>Neuropharmacology</i> , 2016, 101, 68-75.	2.0	20
70	Abuse of New Psychoactive Substances: Threats and Solutions. <i>Neuropsychopharmacology</i> , 2016, 41, 663-665.	2.8	54
71	Clinically Relevant Pharmacological Strategies That Reverse MDMA-Induced Brain Hyperthermia Potentiated by Social Interaction. <i>Neuropsychopharmacology</i> , 2016, 41, 549-559.	2.8	16
72	Interrogating the Activity of Ligands at Monoamine Transporters in Rat Brain Synaptosomes. <i>Neuromethods</i> , 2016, , 41-52.	0.2	2

#	ARTICLE	IF	CITATIONS
73	The Changing Face of Recreational Drug Use. <i>Cerebrum: the Dana Forum on Brain Science</i> , 2016, 2016, .	0.1	4
74	Studies of the Biogenic Amine Transporters 15. Identification of Novel Allosteric Dopamine Transporter Ligands with Nanomolar Potency. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 353, 529-538.	1.3	26
75	Effects of Social Interaction and Warm Ambient Temperature on Brain Hyperthermia Induced by the Designer Drugs Methylone and MDPV. <i>Neuropsychopharmacology</i> , 2015, 40, 436-445.	2.8	36
76	Quantification of methylone and metabolites in rat and human plasma by liquid chromatography-tandem mass spectrometry. <i>Forensic Toxicology</i> , 2015, 33, 202-212.	1.4	9
77	Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter. <i>Drug and Alcohol Dependence</i> , 2015, 147, 1-19.	1.6	116
78	Modafinil and its metabolites enhance the anticonvulsant action of classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. <i>Psychopharmacology</i> , 2015, 232, 2463-2479.	1.5	15
79	Ethylenedioxy homologs of N -methyl-(3,4-methylenedioxyphenyl)-2-aminopropane (MDMA) and its corresponding cathinone analog methylenedioxymethcathinone: Interactions with transporters for serotonin, dopamine, and norepinephrine. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 5574-5579.	1.4	6
80	Synthesis, characterization, and monoamine transporter activity of the new psychoactive substance 3- α ,4- α -methylenedioxy-4-methylaminorex (MDMAR). <i>Drug Testing and Analysis</i> , 2015, 7, 555-564.	1.6	16
81	"Second-Generation"™ Mephedrone Analogs, 4-MEC and 4-MePPP, Differentially Affect Monoamine Transporter Function. <i>Neuropsychopharmacology</i> , 2015, 40, 1321-1331.	2.8	86
82	Stereochemistry of mephedrone neuropharmacology: enantiomer-specific behavioural and neurochemical effects in rats. <i>British Journal of Pharmacology</i> , 2015, 172, 883-894.	2.7	67
83	Critical Role of Peripheral Vasoconstriction in Fatal Brain Hyperthermia Induced by MDMA (Ecstasy) under Conditions That Mimic Human Drug Use. <i>Journal of Neuroscience</i> , 2014, 34, 7754-7762.	1.7	48
84	Effects of 3,4-methylenedioxymethamphetamine (<sc>MDMA</sc>) and its main metabolites on cardiovascular function in conscious rats. <i>British Journal of Pharmacology</i> , 2014, 171, 83-91.	2.7	33
85	Age differences in (\pm) 3,4-methylenedioxymethamphetamine (MDMA)-induced conditioned taste aversions and monoaminergic levels. <i>Developmental Psychobiology</i> , 2014, 56, 635-646.	0.9	12
86	3,4-Methylenedioxypropylone (MDPV) and metabolites quantification in human and rat plasma by liquid chromatography-high resolution mass spectrometry. <i>Analytica Chimica Acta</i> , 2014, 827, 54-63.	2.6	40
87	Pharmacology of novel synthetic stimulants structurally related to the "bath salts" constituent 3,4-methylenedioxypropylone (MDPV). <i>Neuropharmacology</i> , 2014, 87, 206-213.	2.0	176
88	Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes. <i>Psychopharmacology</i> , 2014, 231, 4135-4144.	1.5	64
89	Characterization of a novel and potentially lethal designer drug (\pm)-methyl-4-methylaminorex (4,4'-MDMAR, or "Serotoni"™). <i>Drug Testing and Analysis</i> , 2014, 6, 684-695.	1.5	62
90	Nonlinear Pharmacokinetics of (\pm)3,4-Methylenedioxymethamphetamine (MDMA) and Its Pharmacodynamic Consequences in the Rat. <i>Drug Metabolism and Disposition</i> , 2014, 42, 119-125.	1.7	28

#	ARTICLE	IF	CITATIONS
91	Evidence for a Role of Transporter-Mediated Currents in the Depletion of Brain Serotonin Induced by Serotonin Transporter Substrates. <i>Neuropsychopharmacology</i> , 2014, 39, 1355-1365.	2.8	34
92	Bath Salts, Spice, and Related Designer Drugs: The Science Behind the Headlines. <i>Journal of Neuroscience</i> , 2014, 34, 15150-15158.	1.7	133
93	Awash in a sea of "bath salts": implications for biomedical research and public health. <i>Addiction</i> , 2014, 109, 1577-1579.	1.7	48
94	Alpha-ethyltryptamines as dual dopamine-serotonin releasers. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 4754-4758.	1.0	28
95	Hybrid Dopamine Uptake Blocker-Serotonin Releaser Ligands: A New Twist on Transporter-Focused Therapeutics. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 623-627.	1.3	43
96	Abuse-related effects of dual dopamine/serotonin releasers with varying potency to release norepinephrine in male rats and rhesus monkeys.. <i>Experimental and Clinical Psychopharmacology</i> , 2014, 22, 274-284.	1.3	16
97	Effect of Chronic Delivery of the Toll-like Receptor 4 Antagonist (+)-Naltrexone on Incubation of Heroin Craving. <i>Biological Psychiatry</i> , 2013, 73, 729-737.	0.7	106
98	Psychoactive "Bath Salts": Compounds, Mechanisms, and Toxicities. <i>Neuropsychopharmacology</i> , 2013, 38, 243-244.	2.8	17
99	Psychoactive "bath salts": Not so soothing. <i>European Journal of Pharmacology</i> , 2013, 698, 1-5.	1.7	183
100	Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs. <i>European Journal of Pharmacology</i> , 2013, 699, 180-187.	1.7	46
101	Powerful Cocaine-Like Actions of 3,4-Methylenedioxypyrovalerone (MDPV), a Principal Constituent of Psychoactive "Bath Salts" Products. <i>Neuropsychopharmacology</i> , 2013, 38, 552-562.	2.8	361
102	CB1 "Cannabinoid Receptor Antagonist Effects on Cortisol in Cannabis-Dependent Men. <i>American Journal of Drug and Alcohol Abuse</i> , 2012, 38, 114-119.	1.1	17
103	Studies of the Biogenic Amine Transporters. 14. Identification of Low-Efficacy "Partial" Substrates for the Biogenic Amine Transporters. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 341, 251-262.	1.3	35
104	Differential modulation of cocaine's discriminative cue by repeated and variable stress exposure: Relation to monoamine transporter levels. <i>Neuropharmacology</i> , 2012, 63, 330-337.	2.0	8
105	Medial Prefrontal Cortex Neuronal Activation and Synaptic Alterations after Stress-Induced Reinstatement of Palatable Food Seeking: A Study Using c-fos-GFP Transgenic Female Rats. <i>Journal of Neuroscience</i> , 2012, 32, 8480-8490.	1.7	60
106	The Designer Methcathinone Analogs, Mephedrone and Methylone, are Substrates for Monoamine Transporters in Brain Tissue. <i>Neuropsychopharmacology</i> , 2012, 37, 1192-1203.	2.8	386
107	Effect of fenfluramine on reinstatement of food seeking in female and male rats: implications for the predictive validity of the reinstatement model. <i>Psychopharmacology</i> , 2012, 221, 341-353.	1.5	35
108	Effects of MDMA and related analogs on plasma 5-HT: Relevance to 5-HT transporters in blood and brain. <i>European Journal of Pharmacology</i> , 2012, 674, 337-344.	1.7	25

#	ARTICLE	IF	CITATIONS
109	Effects of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites on cardiovascular function in rats. <i>FASEB Journal</i> , 2012, 26, 1040-7.	0.2	0
110	In Vivo Effects of Amphetamine Analogs Reveal Evidence for Serotonergic Inhibition of Mesolimbic Dopamine Transmission in the Rat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 337, 218-225.	1.3	95
111	Altered Gene Expression in Pulmonary Tissue of Tryptophan Hydroxylase-1 Knockout Mice: Implications for Pulmonary Arterial Hypertension. <i>PLoS ONE</i> , 2011, 6, e17735.	1.1	13
112	Rats preexposed to MDMA display attenuated responses to its aversive effects in the absence of persistent monoamine depletions. <i>Psychopharmacology</i> , 2011, 216, 441-449.	1.5	10
113	Evidence for noncompetitive modulation of substrate-induced serotonin release. <i>Synapse</i> , 2010, 64, 862-869.	0.6	15
114	Serotonin (5-HT) precursor loading with 5-hydroxy-l-tryptophan (5-HTP) reduces locomotor activation produced by (+)-amphetamine in the rat. <i>Drug and Alcohol Dependence</i> , 2010, 114, 147-52.	1.6	22
115	Evidence for the Involvement of Dopamine Transporters in Behavioral Stimulant Effects of Modafinil. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 329, 738-746.	1.3	169
116	Serotonergic drugs and valvular heart disease. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 317-329.	1.0	128
117	Selective Suppression of Cocaine- versus Food-Maintained Responding by Monoamine Releasers in Rhesus Monkeys: Benzylpiperazine, (+)Phenmetrazine, and 4-Benzylpiperidine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 329, 272-281.	1.3	34
118	Effects of Dose and Route of Administration on Pharmacokinetics of (±)-3,4-Methylenedioxymethamphetamine in the Rat. <i>Drug Metabolism and Disposition</i> , 2009, 37, 2163-2170.	1.7	68
119	Neural and Cardiac Toxicities Associated With 3,4-Methylenedioxymethamphetamine (MDMA). <i>International Review of Neurobiology</i> , 2009, 88, 257-296.	0.9	41
120	Appetite Suppressants, Cardiac Valve Disease and Combination Pharmacotherapy. <i>American Journal of Therapeutics</i> , 2009, 16, 354-364.	0.5	60
121	An n-3 fatty acid deficiency impairs rat spatial learning in the Barnes maze.. <i>Behavioral Neuroscience</i> , 2009, 123, 196-205.	0.6	80
122	Serotonin (5-HT) Transporter Ligands Affect Plasma 5-HT in Rats. <i>Annals of the New York Academy of Sciences</i> , 2008, 1139, 268-284.	1.8	20
123	Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. <i>Biochemical Pharmacology</i> , 2008, 75, 2-16.	2.0	77
124	Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain. <i>Pharmacology Biochemistry and Behavior</i> , 2008, 90, 208-217.	1.3	97
125	Dual dopamine/serotonin releasers: Potential treatment agents for stimulant addiction.. <i>Experimental and Clinical Psychopharmacology</i> , 2008, 16, 458-474.	1.3	57
126	Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges. <i>Neuroscience</i> , 2008, 152, 773-784.	1.1	59

#	ARTICLE	IF	CITATIONS
127	Chronic Fenfluramine Administration Increases Plasma Serotonin (5-Hydroxytryptamine) to Nontoxic Levels. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 324, 791-797.	1.3	29
128	Dopamine/serotonin releasers as medications for stimulant addictions. <i>Progress in Brain Research</i> , 2008, 172, 385-406.	0.9	38
129	Dual Dopamine/Serotonin Releasers as Potential Medications for Stimulant and Alcohol Addictions. , 2008, , 311.		3
130	Methamphetamine and Idiopathic Pulmonary Arterial Hypertension. <i>Chest</i> , 2007, 132, 1412-1413.	0.4	17
131	Monoamine Releasers with Varying Selectivity for Dopamine/Norepinephrine versus Serotonin Release as Candidate "Agonist" Medications for Cocaine Dependence: Studies in Assays of Cocaine Discrimination and Cocaine Self-Administration in Rhesus Monkeys. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 320, 627-636.	1.3	70
132	Restoration of 3,4-methylenedioxymethamphetamine-induced 5-HT depletion by the administration of l-5-hydroxytryptophan. <i>Neuroscience</i> , 2007, 148, 212-220.	1.1	20
133	Serotonergic responsiveness in human cocaine users. <i>Drug and Alcohol Dependence</i> , 2007, 86, 207-213.	1.6	14
134	Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions. <i>AAPS Journal</i> , 2007, 9, E1-E10.	2.2	55
135	Neurobiology of 3,4-Methylenedioxymethamphetamine (MDMA, or "Ecstasy"). , 2007, , 119-142.		0
136	Depressive-Like Effects of the μ -Opioid Receptor Agonist Salvinorin A on Behavior and Neurochemistry in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 316, 440-447.	1.3	340
137	Therapeutic Potential of Monoamine Transporter Substrates. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 1845-1859.	1.0	53
138	Dual dopamine"5-HT releasers: potential treatment agents for cocaine addiction. <i>Trends in Pharmacological Sciences</i> , 2006, 27, 612-618.	4.0	39
139	Alterations in alcohol consumption, withdrawal seizures, and monoamine transmission in rats treated with phentermine and 5-hydroxy-L-tryptophan. <i>Synapse</i> , 2006, 59, 277-289.	0.6	20
140	Balance between Dopamine and Serotonin Release Modulates Behavioral Effects of Amphetamine-Type Drugs. <i>Annals of the New York Academy of Sciences</i> , 2006, 1074, 245-260.	1.8	108
141	3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. <i>Psychopharmacology</i> , 2006, 189, 407-424.	1.5	214
142	Effects of stress modulation on morphine-induced conditioned place preferences and plasma corticosterone levels in Fischer, Lewis, and Sprague"awley rat strains. <i>Psychopharmacology</i> , 2006, 189, 277-286.	1.5	33
143	Interaction of Amphetamines and Related Compounds at the Vesicular Monoamine Transporter. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 319, 237-246.	1.3	119
144	Amphetamine Analogs Increase Plasma Serotonin: Implications for Cardiac and Pulmonary Disease. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 318, 604-610.	1.3	56

#	ARTICLE	IF	CITATIONS
145	N-Substituted Piperazines Abused by Humans Mimic the Molecular Mechanism of 3,4-Methylenedioxymethamphetamine (MDMA, or "Ecstasy"). <i>Neuropsychopharmacology</i> , 2005, 30, 550-560.	2.8	211
146	Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon <i>Papio anubis</i> . <i>Synapse</i> , 2005, 56, 94-99.	0.6	47
147	Development of a Rationally Designed, Low Abuse Potential, Biogenic Amine Releaser That Suppresses Cocaine Self-Administration. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 1361-1369.	1.3	83
148	(±)-3,4-Methylenedioxymethamphetamine Administration to Rats Does Not Decrease Levels of the Serotonin Transporter Protein or Alter Its Distribution between Endosomes and the Plasma Membrane. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 1002-1012.	1.3	56
149	Relationship between the Serotonergic Activity and Reinforcing Effects of a Series of Amphetamine Analogs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 848-854.	1.3	182
150	Targeted screening for biogenic amine transporters: Potential applications for natural products. <i>Life Sciences</i> , 2005, 78, 512-518.	2.0	4
151	Development of Neurochemical Normalization (Agonist Substitution) Therapeutics for Stimulant Abuse: Focus on the Dopamine Uptake Inhibitor, GBR12909. <i>Current Medicinal Chemistry - Central Nervous System Agents</i> , 2004, 4, 47-59.	0.6	12
152	Effects of Chronic Social Stress on Neuroendocrine Responsiveness to Challenge with Ethanol, Dexamethasone and Corticotropin-Releasing Hormone. <i>Neuroendocrinology</i> , 2004, 80, 332-342.	1.2	25
153	Substituted Amphetamines That Produce Long-Term Serotonin Depletion in Rat Brain (Neurotoxicity) Do Not Decrease Serotonin Transporter Protein Expression. <i>Annals of the New York Academy of Sciences</i> , 2004, 1025, 151-161.	1.8	12
154	Effects of "Legal" Piperazine Analogs on Dopamine and Serotonin Release in Rat Brain. <i>Annals of the New York Academy of Sciences</i> , 2004, 1025, 189-197.	1.8	66
155	3,4-methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein. <i>Synapse</i> , 2004, 53, 240-248.	0.6	82
156	Synthesis and Pharmacological Evaluation of 3-(3,4-Dichlorophenyl)-1-indanamine Derivatives as Nonselective Ligands for Biogenic Amine Transporters. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 2624-2634.	2.9	56
157	Evidence for alterations in α_2 -adrenergic receptor sensitivity in rats exposed to repeated cocaine administration. <i>Neuroscience</i> , 2004, 125, 683-690.	1.1	33
158	The role of corticosterone in food deprivation-induced reinstatement of cocaine seeking in the rat. <i>Psychopharmacology</i> , 2003, 168, 170-176.	1.5	116
159	Monoamine transporters and psychostimulant drugs. <i>European Journal of Pharmacology</i> , 2003, 479, 23-40.	1.7	414
160	High-dose fenfluramine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrain. <i>Synapse</i> , 2003, 50, 233-239.	0.6	56
161	(+)-Fenfluramine and Its Major Metabolite, (+)-Norfenfluramine, Are Potent Substrates for Norepinephrine Transporters. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 305, 1191-1199.	1.3	70
162	Persistent Antagonism of Methamphetamine-Induced Dopamine Release in Rats Pretreated with GBR12909 Decanoate. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 301, 1190-1197.	1.3	42

#	ARTICLE	IF	CITATIONS
163	Development of Long-Acting Dopamine Transporter Ligands as Potential Cocaine-Abuse Therapeutic Agents: Chiral Hydroxyl-Containing Derivatives of 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(Diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 1321-1329.	2.9	62
164	Endogenous corticotropin releasing factor regulates adrenergic and opioid receptors. <i>Peptides</i> , 2002, 23, 2177-2180.	1.2	10
165	Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. <i>European Journal of Pharmacology</i> , 2002, 447, 51-57.	1.7	67
166	Serotonin releasing agents. <i>Pharmacology Biochemistry and Behavior</i> , 2002, 71, 825-836.	1.3	124
167	Therapeutic and adverse actions of serotonin transporter substrates. , 2002, 95, 73-88.		156
168	Appetite Suppressants as Agonist Substitution Therapies for Stimulant Dependence. <i>Annals of the New York Academy of Sciences</i> , 2002, 965, 109-126.	1.8	38
169	Preclinical Evaluation of GBR12909 Decanoate as a Long-Acting Medication for Methamphetamine Dependence. <i>Annals of the New York Academy of Sciences</i> , 2002, 965, 92-108.	1.8	16
170	Inhibition of MAO-A fails to alter cocaine-induced increases in extracellular dopamine and norepinephrine in rat nucleus accumbens. <i>Molecular Brain Research</i> , 2001, 87, 184-189.	2.5	18
171	Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. <i>Synapse</i> , 2001, 39, 32-41.	0.6	825
172	Autoregulation of dopamine synthesis in subregions of the rat nucleus accumbens. <i>European Journal of Pharmacology</i> , 2001, 411, 107-113.	1.7	8
173	1-(m-Chlorophenyl)piperazine (mCPP) Dissociates In Vivo Serotonin Release from Long-Term Serotonin Depletion in Rat Brain. <i>Neuropsychopharmacology</i> , 2001, 24, 492-501.	2.8	56
174	Chapter 5 Comparative neuropharmacology of ibogaine and its O-desmethyl metabolite, noribogaine. <i>The Alkaloids Chemistry and Biology</i> , 2001, 56, 79-113.	0.8	33
175	Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse. , 2000, 35, 222-227.		75
176	Neurochemical mechanisms of phentermine and fenfluramine: Therapeutic and adverse effects. <i>Drug Development Research</i> , 2000, 51, 52-65.	1.4	26
177	Methamphetamine Dependence: Medication Development Efforts Based on the Dual Deficit Model of Stimulant Addiction. <i>Annals of the New York Academy of Sciences</i> , 2000, 914, 71-81.	1.8	18
178	Serotonin Transporters, Serotonin Release, and the Mechanism of Fenfluramine Neurotoxicity. <i>Annals of the New York Academy of Sciences</i> , 2000, 914, 172-186.	1.8	18
179	Noribogaine (12-Hydroxyibogamine): A Biologically Active Metabolite of the Antiaddictive Drug Ibogaine. <i>Annals of the New York Academy of Sciences</i> , 2000, 914, 354-368.	1.8	30
180	Differential neuroendocrine responsiveness to morphine in Lewis, Fischer 344, and ACI inbred rats. <i>Brain Research</i> , 2000, 858, 320-326.	1.1	24

#	ARTICLE	IF	CITATIONS
181	Evidence for Possible Involvement of 5-HT _{2B} Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications. <i>Circulation</i> , 2000, 102, 2836-2841.	1.6	659
182	Comparative neurobiological effects of ibogaine and MK-801 in rats. <i>Drug and Alcohol Dependence</i> , 2000, 59, 143-151.	1.6	11
183	Neurochemical mechanisms of phentermine and fenfluramine: Therapeutic and adverse effects. , 2000, 51, 52.		1
184	Aminorex, Fenfluramine, and Chlorphentermine Are Serotonin Transporter Substrates. <i>Circulation</i> , 1999, 100, 869-875.	1.6	201
185	Effects of dopamine and serotonin-releasing agents on methamphetamine discrimination and self-administration in rats. <i>Psychopharmacology</i> , 1999, 141, 287-296.	1.5	67
186	Discovery of novel peptidic dopamine transporter ligands by screening a positional scanning combinatorial hexapeptide library. , 1999, 33, 239-246.		10
187	Phentermine and Fenfluramine: Preclinical Studies in Animal Models of Cocaine Addiction. <i>Annals of the New York Academy of Sciences</i> , 1998, 844, 59-74.	1.8	47
188	In Vivo Correlates of Central Serotonin Function after High-Dose Fenfluramine Administration. <i>Annals of the New York Academy of Sciences</i> , 1998, 844, 138-152.	1.8	7
189	Systemically administered cocaine alters stimulus-evoked responses of thalamic somatosensory neurons to perithreshold vibrissae stimulation. <i>Brain Research</i> , 1998, 798, 7-17.	1.1	25
190	Effects of cocaethylene on dopamine and serotonin synthesis in Long-Evans and Sprague-Dawley brains. <i>Brain Research</i> , 1998, 804, 316-319.	1.1	7
191	Orphanin FQ stimulates prolactin and growth hormone release in male and female rats. <i>Brain Research</i> , 1998, 807, 228-233.	1.1	50
192	Combined phentermine/fenfluramine administration and central serotonin neurons. <i>Synapse</i> , 1998, 28, 339-342.	0.6	6
193	Alterations in serotonergic responsiveness during cocaine withdrawal in rats: similarities to major depression in humans. <i>Biological Psychiatry</i> , 1998, 44, 578-591.	0.7	87
194	Neurochemical and Neuroendocrine Effects of Ibogaine in Rats: Comparison to MK-801. <i>Annals of the New York Academy of Sciences</i> , 1998, 844, 252-264.	1.8	9
195	Functional Consequences of Central Serotonin Depletion Produced by Repeated Fenfluramine Administration in Rats. <i>Journal of Neuroscience</i> , 1998, 18, 9069-9077.	1.7	44
196	Behavioural and neurochemical characteristics of phentermine and fenfluramine administered separately and as a mixture in rats. <i>Psychopharmacology</i> , 1997, 131, 296-306.	1.5	41
197	Effects of phentermine and cocaine on fenfluramine-induced depletion of serotonin in mouse brain. <i>Drug and Alcohol Dependence</i> , 1996, 41, 71-74.	1.6	8
198	Chronic cocaine exposure potentiates prolactin and head shake responses to 5-HT ₂ receptor stimulation in rats. <i>Neuropharmacology</i> , 1996, 35, 295-301.	2.0	26

#	ARTICLE	IF	CITATIONS
199	Phentermine pretreatment antagonizes the cocaine-induced rise in mesolimbic dopamine. <i>NeuroReport</i> , 1996, 8, 7-9.	0.6	15
200	Neuroendocrine and neurochemical effects of acute ibogaine administration: a time course evaluation. <i>Brain Research</i> , 1996, 737, 215-220.	1.1	25
201	Endocrine responses during acute nicotine withdrawal. <i>Pharmacology Biochemistry and Behavior</i> , 1996, 55, 433-437.	1.3	26
202	Inhibition of Tuberoinfundibular Dopaminergic Neural Activity During Suckling: Involvement of δ and μ Opiate Receptor Subtypes. <i>Journal of Neuroendocrinology</i> , 1996, 8, 771-776.	1.2	45
203	The serotonin agonist m-chlorophenylpiperazine (mCPP) binds to serotonin transporter sites in human brain. <i>NeuroReport</i> , 1995, 6, 2150-2152.	0.6	48
204	Repeated cocaine administration reduces 5-HT _{1A} -mediated prolactin secretion in rats. <i>Neuroscience Letters</i> , 1995, 193, 9-12.	1.0	19
205	Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. <i>Life Sciences</i> , 1995, 57, PL45-PL50.	2.0	93
206	Evidence for alterations in presynaptic serotonergic function during withdrawal from chronic cocaine in rats. <i>European Journal of Pharmacology</i> , 1995, 282, 87-93.	1.7	46
207	Effects of intravenous cocaine on plasma cortisol and prolactin in human cocaine abusers. <i>Biological Psychiatry</i> , 1995, 38, 751-755.	0.7	88
208	Monoaminergic Regulation of Neuroendocrine Function and Its Modification by Cocaine. <i>Frontiers in Neuroendocrinology</i> , 1994, 15, 85-156.	2.5	69
209	Lack of evidence for context-dependent cocaine-induced sensitization in humans: Preliminary studies. <i>Pharmacology Biochemistry and Behavior</i> , 1994, 49, 583-588.	1.3	75
210	Nitric oxide inhibits [³ H]dopamine uptake. <i>Brain Research</i> , 1994, 641, 83-91.	1.1	173
211	Biosynthesis of dopamine and serotonin in the rat brain after repeated cocaine injections: A microdissection mapping study. <i>Synapse</i> , 1993, 14, 40-50.	0.6	54
212	Effects of acute and chronic cocaine on the activity of tuberoinfundibular dopamine neurons in the rat. <i>Brain Research</i> , 1993, 608, 175-179.	1.1	21
213	Withdrawal from chronic cocaine enhances behavioral sensitivity to the 5-HT ₂ /1C agonist DOI. <i>Biological Psychiatry</i> , 1993, 34, 576-577.	0.7	18
214	Inhibition of suckling-induced prolactin release by δ - and μ -opioid antagonists. <i>Brain Research</i> , 1991, 567, 224-230.	1.1	30
215	Mu-Selective Opioid Peptides Stimulate Prolactin Release in Lactating Rats. <i>Journal of Neuroendocrinology</i> , 1990, 2, 271-276.	1.2	12